Clinical Trials Logo
NCT number NCT00000172
Study type Interventional
Source National Institute on Aging (NIA)
Contact
Status Completed
Phase Phase 3

Clinical Trial Summary

Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve cells in the brain responsible for memory and cognitive function communicate using a chemical called acetylcholine. Research has shown that deterioration of cells that produce acetylcholine in the brain affects thought processes. Galantamine is thought to work in two ways to increase the amount of acetylcholine available in the brain. It inhibits an enzyme that breaks down acetylcholine and it also stimulates the nicotinic receptors in the brain to release more acetylcholine.


Clinical Trial Description

After a 1-month single-blind run in phase, 910 subjects will be titrated, over a period of up to 8 weeks, to target doses of either: 0 (placebo); 24 mg/day galantamine; 16 mg/day galantamine; or 8 mg/day galantamine, in a 2:2:2:1 randomization ratio. Double-blind treatment will continue for a total of 5 months. The change from baseline in ADAS-cog and CIVIC-plus scores at Month 5 will be the primary efficacy endpoints. Tolerability will be evaluated based on adverse event reports, laboratory values, ECG, and vital signs with particular focus on the adverse event rates in the slower titration schedule for 24 mg/day. Efficacy of 24 mg/day and 16 mg/day galantamine will be compared with that of placebo. Information on the dose response relationship of galantamine will be evaluated.


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Not yet recruiting NCT03208491 - AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders N/A
Recruiting NCT03056495 - Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease Phase 1
Recruiting NCT03095417 - Improving the Recovery and Outcome Every Day After the ICU N/A
Not yet recruiting NCT03256539 - Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease N/A
Not yet recruiting NCT03116126 - Noradrenergic Add-on Therapy With Guanfacine Phase 3
Recruiting NCT02835716 - Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO N/A
Recruiting NCT02253732 - Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs N/A
Recruiting NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Active, not recruiting NCT02172612 - A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly N/A
Completed NCT03034746 - Impact of Physical Activity on Successful Aging N/A
Completed NCT01823666 - Predicting the Conversion From Mild Cognitive Impairment to Dementia N/A
Completed NCT01582919 - Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study N/A
Completed NCT01436188 - A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease Phase 0
Completed NCT01409694 - Alzheimer's Disease - Input of Vitamin D With mEmantine Assay Phase 3
Recruiting NCT01638884 - Prospective Memory Imaging N/A
Recruiting NCT01128725 - Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers N/A
Completed NCT01217021 - Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 Phase 0
Completed NCT00912886 - Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease N/A
Completed NCT00956410 - To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients Phase 2